Pharma Research Library | Pharma Info Index Research | Innovation | Opportunities |

Lumoxiti injection is a new medicine for intravenous use for the treatment of adult patients with refractory hairy cell leukemia (HCL) who have received minimum two prior systemic therapies, including treatment with a purine nucleoside analog. Lumoxiti is a CD22-directed cytotoxin and very first drug of this type of treatment for patients with HCL. It is rare and slow growing ... Read More »